Subjective well-being, craving for cannabis and compliance or medication switch in a randomized double blind study with olanzapine and risperidone

Trial Profile

Subjective well-being, craving for cannabis and compliance or medication switch in a randomized double blind study with olanzapine and risperidone

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Dec 2009

At a glance

  • Drugs Olanzapine; Risperidone
  • Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
  • Focus Pharmacodynamics
  • Acronyms SUB-CAN-OLA-RIS
  • Most Recent Events

    • 03 Dec 2009 Trial acronym SUB-CAN-OLA-RIS identified as reported by Netherlands Trial Register.
    • 03 Dec 2009 New source identified and integrated (Netherlands Trial Register NTR28).
    • 23 Sep 2008 Status changed from not stated to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top